The NIHSS and Barthel Index both Tanto la escala NIHSS como el análisis y una interpretación más robustos. NIHSS. Índice de Barthel. Escala de Rankin. 21 fev. Características do teste. Introdução Conclusão Escalas – medidas objectivas que permitem. Comunicação cientifica entre profissionais. 2, en la escala NIHSS. – Escala Rankin modificada previa al ictus? 2. que puedan interferir en la interpretación de las escalas neurológicas.
|Published (Last):||3 April 2008|
|PDF File Size:||14.93 Mb|
|ePub File Size:||19.99 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.
National Institutes of Health Stroke Scale
Pneumonia AND sponsor name. How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field.
Trials with results Trials without results Clear advanced search filters. Review by the Competent Authority or Ethics Committee in the country concerned. EU Clinical Trials Register. Both Female Only Male Only.
Clinical Trials Register
IMP with orphan designation in the indication. Trials with results Trials without results.
Clear advanced search filters. Date on which this record was first entered in the EudraCT database:.
Title of the trial for lay people, in easily understood, i. Study to see if riboflavin reduces neuronal damage in patients with acute ischemic stroke. The IMP has been designated in this indication as an orphan drug in the Community.
Manejo inicial del ictus isquémico agudo
Committee on Advanced therapies CAT has issued a classification for this product. Combination product that includes a fscala, but does not involve an Advanced Therapy. Study whether patients with acute ischemic stroke and treated with CBG riboflavin have lower ingerpretacion stay than those who receiving placebo. Study if patients with acute ischemic stroke and were treated with CBG riboflavin have a higher percentage of clinical improvement basal-high than those who receiving placebo.
Consider whether patients with acute ischemic stroke and treated with CBG riboflavin have a better functional outcome than those who receiving placebo.
Investigate the variations of serum glutamate levels among acute ischemic stroke patients treated with CBG riboflavin or placebo. Explore whether the prognosis of patients receiving CBG riboflavin and have no stroke is not worse than those treated with placebo.
Assess if CBG riboflavin administration in patients with clinical suspicion of stroke, administered within the first interretacion hours of onset is safe. The trial involves single site in the Member State concerned.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial.
Patients arriving at the emergency room with a low degree of consciousness. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.